Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2026

Genmab — Januar 2026

Planlagt Fastgjort Låst Flyttet Genmab
295 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Raun
    wrote on sidst redigeret af
    #169

    I mine øjne vil jeg ikke give dig ret @Sukkeralf ..... Der er en faktor der har gjort den store forskel og det er købet af Merus.... Er klar over Darzalex patent udløb om 4-5år, men med de godter Genmab i tiden skilter med. - Der burde være en langt højere forventning til at fremtiden ser lys ud - hvilket burde spejle sig i langt højere grad i
    P/E værdien

    1 Reply Last reply
    0
    • S Offline
      S Offline
      Sukkeralf
      wrote on sidst redigeret af
      #170

      Ikke sikker på jeg forstår hvad du mener om Merus købet? Aktien steget ca halvdelen af de 55 procent siden det blev offentliggjort.

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #171

        Med hensyn til Darzalex så er det jo faste indtægter, mens alle de tiltag Genmab laver giver forhåbninger om indtægter fremadrettet, men vi ved jo ikke om de kommer, hvor meget det bliver og hvor hurtigt. Og går epco, rita og peto igennem så skal det nok blive godt, men det har jo stadig meget lange udsigter - så i takt med positive fase III kommer i hus, så skal kursen nok stige stille og roligt.

        1 Reply Last reply
        0
        • G Offline
          G Offline
          gentogen
          wrote on sidst redigeret af
          #172

          Hvis nu Genmab havde haft PFS og andel CR som primært endpoint, så ville alle tale om mega succes...

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #173

            Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum https://pharmadevicenews.com/can-epcoritamab-reshape-salvage-dlbcl-care-genmabs-phase-3-data-brings-regulatory-momentum/

            1 Reply Last reply
            0
            • N Offline
              N Offline
              NiklasZ
              wrote on sidst redigeret af
              #174

              @EL Do not mention Grok... you risk awakening the trolls from the Tesla ch
              at. 😄

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #175

                Godmorgen 🙂

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #176

                  lol, i'll say Perplexity next time 😉 . I try to Buy European given the current political climate, but unfortunately we are dangerously behind here on these things...

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #177

                    just to put friday's price action into perspective; expert Hutchings compares the data to STARGLO https://x.com/DocHutchings/status/2012577901636362506 , which is Glofitamab plus chemo, while the epco DLBCL-1 data is monotherapy and has a different population. i really don't think you can do that

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #178

                      if even experts like him make these mistakes, just think about the average investor...

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #179

                        (and by the way, tomorrow is a US holiday, Martin Luther King day, which presumably will have impacted volume on this late friday news)

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #180

                          Teclistamab Monotherapy Improves OS and PFS Over SOC in Relapsed/Refractory Multiple Myeloma -reducing disease progression or death risk by 71% and death risk by 40%. -the Independent Data Monitoring Committee recommended unblinding the trial based on the strength of the results.
                          https://www.onclive.com/view/teclistamab-monotherapy-improves-os-and-pfs-over-soc-in-relapsed-refractory-multiple-myeloma

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #181

                            Godmorgen 🙂

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #182

                              Genmab viser igen gode takter med kræftmiddel i fase 3-studie https://proinvestor.com/investornyt/1404446/genmab-viser-igen-gode-takter-med-kraeftmiddel-i-fase-3-studie

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Stroka
                                wrote on sidst redigeret af
                                #183

                                God morgen. 🙂

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #184

                                  How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma https://pharmadevicenews.com/how-abbvies-epcoritamab-reshapes-the-competitive-calculus-in-relapsed-diffuse-large-b-cell-lymphoma/

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #185

                                    this article addresses a lot of the points mentioned here

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #186

                                      Matt Phipps
                                      William Blair
                                      Buy Reiterated https://longbridge.com/en/news/272881086?channel=WHAB0002

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #187

                                        and https://www.tipranks.com/news/ratings/genmab-limited-epkinly-approval-risk-and-high-value-2026-pipeline-catalysts-support-buy-rating-ratings

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #188

                                          James Gordon CFA
                                          Barclays
                                          Buy Kr.2,500.00 Maintained Today

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper